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METRONOMIC CHEMOTHERAPY: ROLE IN DEVELOPING COUNTRIES FOR HEAD 
AND NECK CANCER
Head and neck squamous cell carcinoma (HNSCC) is one 
of the countries.[1] More than half of the patients present 
in advanced stage.[2,3] The number of institutes providing 
cancer care is highly inadequate in developing countries. 
A cross-sectional study on head and neck cancers (HNC) 
showed that various beliefs (‘cancer is a curse’), non-
availability of transport, believing mouth ulcer to be self-
limiting and prolonged treatment resulting in family stress 
are important factors in treatment delay.[4] Other reasons 
included poor socioeconomic status of the patient, cost 
of care and high rate of illiteracy.[5] The current pricing 
system of chemotherapy drugs is unsustainable and not 
affordable for many patients on palliative care. There is 
an enormous financial pressure on the society, especially 
in developing countries due to the skyrocketing costs.[6] 
In these patients, already in advanced stage of cancer, 
poor access to the specialized cancer centres is further 
compounded with increasingly long waiting lists for 
treatment. A prospective observational study on 201 HNC 
patients showed that there was a delay of 6 months from 
the onset of symptoms to final treatment.[7] Thus, there was 
a need to initiate a therapy that might inhibit progression 
of tumour and keep patients operable during this delay. 
The therapy should have minimal toxicity, economical 
and easy to administer which becomes very important 
for low- to middle-income developing Asian countries.
Metronomic chemotherapy (MC) is one such emerging 
therapeutic option in clinical oncology. The term 
‘metronomic’ is derived from the musical device 
‘metronome’ that produces an audible beat - a click or 
other sound - at regular intervals. In the same way, MC 
is the regular administration of low-dose chemotherapy 
(1/10th–1/3rd of the maximum tolerated dose) that results 
in a constant low blood level of the drug.[8]
MC exerts its anticancer activity by inhibiting tumour 
angiogenesis, stimulating anticancer immune response 
and inducing tumour dormancy.[8] The MC antiangiogenic 
effect was demonstrated by Browder (cyclophosphamide-
based MC) and Klement (vinblastine-based MC).[9,10] 
MC also acts on the innate and adaptive immunity. It has 
been shown that MC selectively induced reduction of 
circulating regulatory T-cells and subsequent reduction 
of their inhibitory functions on antigen-specific immune 
response.[11] Tumour dormancy is mainly due to 
angiogenic dormancy (inability of tumour cells to recruit 
blood vessels), cellular dormancy (tumour cells in G0–
G1 arrest) and immune surveillance (prevent residual 
tumour cells expansion).[8] MC has been used mainly in 
the palliative settings; however, it can also been tried in 
the adjuvant and neoadjuvant settings.
MC in Palliative Settings
Prospective studies have shown that MC as compared 
to single-agent cisplatin chemotherapy, in patients with 
metastatic, relapsed or inoperable HNC[12,13] may be 
beneficial. Results showed a significant better progression-
free survival (PFS) (249 days vs. 152 days, P = 0.02) and 
overall survival (OS) (101 days vs. 66 days, P = 0.014) 
in MC than cisplatin-based chemotherapy with better 
pain control. A retrospective study evaluated the role 
of MC maxillary sinus cancer patients on palliative 
treatment. It showed that the estimated median survival 
in patients with an event-free period after the last therapy 
of <6 months was 45 days, whereas it was 409 days in 
patients with an event-free period post last therapy >6 
months (P = 0.063).[14]
However, no head-to-head studies have been done 
comparing MC to the standard of care drug regimen 
of TPF/cetuximab in this setting. A retrospective study 
of 60 patients with metastatic/recurrent head and neck 
squamous cell cancer treated with weekly paclitaxel 
(80 mg/m2) and cetuximab were matched with 60 patients 
treated with oral MC. The median OS was 191 days in 
metronomic cohort and 256 days in cetuximab cohort. 
The hazard ratio was 0.58 in favour of cetuximab cohort 
(P = 0.031).[15] However, cetuximab, being a significantly 
more expensive therapy, may not be feasible routinely 
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in low- and middle-resource countries such as India and 
Pakistan. Complete remission was seen in two patients, 
partial remission in seven patients, stable disease in 
four patients, and progressive disease in two patients 
in a single-arm prospective observational study of 15 
patients who received MC in the form of oral methotrexate 
(15 mg/m2/week), oral celecoxib (200 mg twice daily) 
and erlotinib (150 mg once daily). The median estimated 
PFS was 148 days. Six patients (40%) showed Grade III/
IV toxicity. Thus, addition of erlotinib showed promising 
results in improving PFS, but proper selection of patients 
is essential as 40% had Grade III/IV toxicity.[16] Mateen 
et al.[17] presented their experience with MC in recurrent 
HNSCC. A total of 72 patients were enrolled and were 
prescribed oral methotrexate 2.5 mg twice in a week and 
capecitabine 500 mg twice a day, for at least 6 months. 
2-year PFS and OS were 18% and 40%, respectively. 
Partial response was seen in 17 (29%) patients while 31 
(54%) patients showed stable disease at 6-month follow-
up. However, this is preliminary data and the complete 
article is yet too published.
MC in the Adjuvant Setting for HNC
The use of MC in the adjuvant setting is still investigational. 
Pandey et al.[18] published a retrospective study of 225 
patients with locally advanced operable oral cavity 
carcinoma (Stage III/IVA) where adjuvant MC {oral 
methotrexate (15 mg/m2) once a week and celecoxib 
(200 mg twice a day) daily} was given in 130/225 (58%) 
patients after completion of the standard treatment for 
a duration of 18 months. The use of MC improved OS 
(14 months vs. 26 months, P = 0.04) and disease-free 
survival (DFS) (8 months vs. 4 months, P = 0.22). None 
of the patients discontinued MC due to toxicity. Lam 
et al. reported that the first prospective randomized 
trial in which a trend of better control of the distant 
metastasis was observed in the adjuvant MC (29 patients: 
Levamisole/uracil-tegafur [UFT] therapy) group (10% 
vs. 32% for the control group [34 patients]). However, 
5-year disease-free actuarial survival rates for patients 
with and without adjuvant MC were 57% and 39%, 
respectively (P = 0.207).[19] Fujii et al.[20] also reported 
that adjuvant chemotherapy with UFT was efficacious for 
treating maxillary sinus carcinoma. The 5-year survival 
was 76.2% for the UFT group and 17.9% for the control 
group. An on-going non-randomized Phase II study in 
Taiwan (NCT00855881) will look into the effect of 1-year 
maintenance treatment of metronomic tegafur-uracil in 
HNSCC.
MC in Neoadjuvant Setting
Studies have shown that MC strategy was associated with 
a reasonable response rate in neoadjuvant settings for 
breast cancers.[21] However, the role of MC in neoadjuvant 
setting for HNC is yet to be studied. A randomized 
controlled trial assessing addition of neoadjuvant and 
maintenance oral MC to standard surgery and adjuvant 
therapy in Stage III/IV operable oral cancers is ongoing 
(CTRI no. CTRI/2015/01/005405). The primary endpoint 
of this study is disease-free survival at 3 years. The 
secondary endpoint is to assess the safety, toxicity and 
tumour response to neoadjuvant MC.
Thus, clinical studies have shown that MC is a promising 
strategy in the management of locally advanced head-
neck cancers. It may be especially relevant to patients 
in the developing countries as it is economical, easy to 
administer without the need for dedicated oncology setups 
or day-care centres. Patients with advanced head-neck 
cancers, especially oral cancers tend to be nutritionally 
deprived, cachectic and may not tolerate conventional 
chemotherapy easily. Treatment with MC is an attractive 
option in these patients who would otherwise have been 
deemed only for symptomatic, palliative care. Overall, 
in unresectable or recurrent or metastatic HNC, MC has 
shown good disease control rates with good quality of 
life outcomes. It should be considered, especially when 
standard chemotherapy (TPF/cetuximab) may not be 
feasible due to fitness, logistic or economic issues.
The role of MC in adjuvant setting has shown promising 
results in clinical trials and can be considered for 
maintenance therapy. Combination of MC with other 
therapies might help in improving response rates. The 
role of maintenance MC in patients who undergo salvage 
surgery also needs validation. Several clinical trials under 
design or in progress will clarify the best dose, schedule, 
optimal sequence and timing of administration. There is 
a number of MC regimen available which need further 
standardization. Nevertheless, there is no unanimous 
consensus for the use of one MC regimen over the other, 
due to the small study population studies. The role of 
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MC in sensitizing the tissue to radiation is also yet to be 
studied. 
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